emerging alk/ros1 tkis for nsclc
Published 7 years ago • 611 plays • Length 4:49Download video MP4
Download video MP3
Similar videos
-
4:05
the evolution of alk/ros1-targeted therapy in nsclc
-
3:31
the evolution of alk/ros1-targeted tkis
-
4:43
upfront therapy for alk/ros1-rearranged nsclc
-
1:06
dr. goldman on targeted therapy options for egfr-, alk-, and ros1-mutated nsclc
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc
-
25:07
2020 ttf alk session - lin - tkis for ros1
-
3:55
treatment considerations in alk/ros-1–rearranged nsclc
-
8:25
egfr & alk/ros1 testing in squamous nsclc
-
4:55
ros1-rearranged nsclc
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc
-
2:27
fish: nsclc (non-small cell lung cancer) alk1 & ros1
-
6:30
treatment options for alk/ros1 mutation
-
3:31
alk/ros1-rearranged nsclc: approaching therapy
-
29:51
current & emerging approaches to acquired resistance for alk/ros1
-
1:12
dr riess on treatment developments in alk and ros1 nsclc
-
5:30
sequencing therapy in alk/ros1-rearranged nsclc
-
2:12
dr. drilon on entrectinib in patients with ros1-positive nsclc
-
6:27
alk inhibitor sequencing in nsclc
-
1:09
dr. camidge on crizotinib as a ros1 inhibitor in nsclc